Medical assessment of adverse health outcomes in Dutch childhood cancer survivors; a nationwide project; SKION LATER Q2008 onderzoek: Adult growth hormone deficiency in childhood cancer survivors

Medical assessment of adverse health outcomes in Dutch childhood cancer survivors; a nationwide project; SKION LATER Q2008 onderzoek: Adult growth hormone deficiency in childhood cancer survivors - SKION LATER Q2008 - adult growth hormone deficiency

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47806

Enrollment

1500

Registered

2015-01-23

Start date

2016-05-04

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

growth hormone deficiency in childhood cancer survivors late pituitary growth hormone deficiency effects of treatment for childhood cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: treated with radiotherapy. Age >= 18 years, >= 5 years off tumor treatment, on stable concomitant medications for 1 month prior to entry of study, otherwise normal pituitary function or on stable hormonal replacement, no treatment for growth hormone deficiency at the time of the tests

Exclusion criteria

Exclusion criteria: pregnancy, active neoplasm, abnormal pituitary functions or recently started concomitant medications

Design outcomes

Primary

Measure	Time frame
* Objective 1: free/bioactive, total IGF-1 concentrations, and their age and gender corrected standard deviation score (SDS-score). * Objective 2: diagnostic accuracy of free and total IGF-1 concentrations in the identification of growth hormone deficiency.	—

Countries

Netherlands

Outcome results